Art. -Nr.: HY-16967

MM41

Kundenbewertung

Based on 1 Customer Validation

MM41 is a quadruplex-interacting compound. MM41 binds tightly to quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes. MM41 reduces BCL-2 and k-RAS protein levels, increases caspase 3. MM41 has antitumor effects against pancreatic cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.89%
CAS. Nr.: 1429028-96-5
Formel: C₄₄H₆₆N₁₀O₆
Molecular Weight:831.06

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

MM41 Chemical Structure

CAS. Nr.: 1429028-96-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Caspase 3

Bcl-2

K-RAS

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Alle Ras Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.32 μM Compound: 3d	Cytotoxicity against human 786-0 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human 786-0 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 23514618]
A549	IC₅₀	<0.01 μM Compound: 3d	Cytotoxicity against human A549 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 23514618]
A549	IC₅₀	19 nM Compound: MM41	Growth inhibition of human A549 cells after 96 hrs by SRB assay Growth inhibition of human A549 cells after 96 hrs by SRB assay	[PMID: 29356532]
MCF7	IC₅₀	0.07 μM Compound: 3d	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 23514618]
MCF7	IC₅₀	70 nM Compound: MM41	Growth inhibition of human MCF7 cells after 96 hrs by SRB assay Growth inhibition of human MCF7 cells after 96 hrs by SRB assay	[PMID: 29356532]
MIA PaCa-2	IC₅₀	0.01 μM Compound: 3d	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 23514618]
MIA PaCa-2	IC₅₀	11 nM Compound: MM41	Growth inhibition of human MIAPaCa2 cells after 96 hrs by SRB assay Growth inhibition of human MIAPaCa2 cells after 96 hrs by SRB assay	[PMID: 29356532]
PANC-1	IC₅₀	0.003 μM Compound: 2a	Cytotoxicity against human PANC1 cells after 96 hrs by SRB assay Cytotoxicity against human PANC1 cells after 96 hrs by SRB assay	[PMID: 23769166]
PANC-1	IC₅₀	3 nM Compound: MM41	Growth inhibition of human PANC1 cells after 96 hrs by SRB assay Growth inhibition of human PANC1 cells after 96 hrs by SRB assay	[PMID: 29356532]
RCC4	IC₅₀	0.56 μM Compound: 3d	Cytotoxicity against human RCC4 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human RCC4 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 23514618]
WI-38	IC₅₀	0.23 μM Compound: 3d	Cytotoxicity against human WI38 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human WI38 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 23514618]
WI-38	IC₅₀	230 nM Compound: MM41	Growth inhibition of human WI38 cells after 96 hrs by SRB assay Growth inhibition of human WI38 cells after 96 hrs by SRB assay	[PMID: 29356532]

In Vitro

MM41 (1 μM) stabilizes the BCL-2 promoter G-quadruplex with a ΔTₘ value of 26.4 °C, and also binds effectively to k-RAS1 and k-RAS2 promoter G-quadruplexes with ΔTₘ values of 22.5 °C and 19.8 °C respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MM41 (10-15 mg/kg; i.v.; twice weekly; 12 doses) shows dose-dependent anti-tumour activity in MIA PaCa-2 pancreatic cancer xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female CD-1 nude mice (2-3 months old, weighing 20-25 g) bearing MIA PaCa-2 pancreatic cancer subcutaneous xenografts^[1]
Dosage:

10 mg/kg, 15 mg/kg
Administration:

Intravenous administration, twice weekly, 12 doses
Result:

Resulted in an average reduction of ca 80% in tumor growth by day 40 in mice, cessation of tumor regrowth from day 30 onwards, and complete tumor regression in two mice with no regrowth for 239 days (15 mg/kg).
Showed weaker anti-tumour effect (10 mg/kg).
Showed reduced BCL-2 and k-RAS protein levels in treated tumours.
Showed that treated tumours, but not untreated ones, show high levels of caspase 3 staining.

Chemical Information

CAS. Nr. 1429028-96-5
Appearance Solid
Molecular Weight 831.06
Formel C₄₄H₆₆N₁₀O₆
Color Blue to purple
SMILES

O=C1C2=CC(NCCCN3CCN(CC3)C)=C4C(N(CCCN5CCOCC5)C(C6=CC(NCCCN7CCN(CC7)C)=C(C2=C64)C(N1CCCN8CCOCC8)=O)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

1 M HCl : 100 mg/mL (120.33 mM; Need ultrasonic)

DMSO : 33.33 mg/mL (40.11 mM; ultrasonic and adjust pH to 8 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2033 mL

6.0164 mL

12.0328 mL

5 mM

0.2407 mL

1.2033 mL

2.4066 mL

10 mM

0.1203 mL

0.6016 mL

1.2033 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ohnmacht SA, et al. A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. Sci Rep. 2015 Jun 16;5:11385. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / 1 M HCl	1 mM	1.2033 mL	6.0164 mL	12.0328 mL	30.0821 mL
	5 mM	0.2407 mL	1.2033 mL	2.4066 mL	6.0164 mL
	10 mM	0.1203 mL	0.6016 mL	1.2033 mL	3.0082 mL
	15 mM	0.0802 mL	0.4011 mL	0.8022 mL	2.0055 mL
	20 mM	0.0602 mL	0.3008 mL	0.6016 mL	1.5041 mL
	25 mM	0.0481 mL	0.2407 mL	0.4813 mL	1.2033 mL
	30 mM	0.0401 mL	0.2005 mL	0.4011 mL	1.0027 mL
	40 mM	0.0301 mL	0.1504 mL	0.3008 mL	0.7521 mL
1 M HCl	50 mM	0.0241 mL	0.1203 mL	0.2407 mL	0.6016 mL
	60 mM	0.0201 mL	0.1003 mL	0.2005 mL	0.5014 mL
	80 mM	0.0150 mL	0.0752 mL	0.1504 mL	0.3760 mL
	100 mM	0.0120 mL	0.0602 mL	0.1203 mL	0.3008 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MM41

MCE Bioactive Compound Library

KRAS Targeted Compound Library

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle Ras Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MM41

MCE Bioactive Compound Library

KRAS Targeted Compound Library

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle Ras Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MM41 Related Classifications

HY-16967 Related Classifications